IXICO plc AGM Statement and Board Changes (4403C)
22 January 2018 - 6:00PM
UK Regulatory
TIDMIXI
RNS Number : 4403C
IXICO plc
22 January 2018
22 January 2018
IXICO plc
("IXICO" or the "Company")
AGM Statement and Board Changes
Building scale and momentum with commercially-led growth
strategy
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, will hold its Annual General Meeting at 9.30am today
at the offices of FTI Consulting LLP, 200 Aldersgate, London, EC1A
4HD.
At the meeting Charles Spicer, the Company's Chairman will make
the following statement:
"The year ended 30 September 2017 was a year of change for the
Company, with a renewed focus on our biopharmaceutical customers. I
am pleased to report a strong performance with increased revenue
and reduced operating losses.
"We ended the year by announcing two new contracts in
Huntington's disease, closely followed by our first two wearable
biosensor contracts. These four contracts have a combined value of
c. GBP3m and, together with our existing contracted revenues,
represent a firm foundation from which we plan to execute our
commercially-led growth strategy. The new year has started well and
we are focused on accelerating the momentum built over the last
year.
"We also announce that Derek Hill is stepping down from the
Board as an Executive Director today. He will cease to be an
employee from 31 March 2018 and will maintain his close
relationship with IXICO in a scientific advisory capacity. Derek is
a founder of IXICO and has been instrumental in growing the
business and transitioning it from a private company to a plc. I
have worked with Derek since 2013 and seen the Company grow and
develop under his leadership. On behalf of the Board I would like
to thank Derek for his hard work and wish him well in his future
endeavours."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20
Officer 3763 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Edward Mansfield / Anita Ghanekar 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMBLMATMBJBBPP
(END) Dow Jones Newswires
January 22, 2018 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024